Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Rawlins

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|November 26, 2004
NICE and the public healthMichael D Rawlins
Nature Reviews. Drug Discovery|April 3, 2004
Cutting the cost of drug development?Michael D Rawlins
Journal of the Royal Society of Medicine|January 30, 2013
Of snarks, boojums and national drug chartsMichael D Rawlins
Clinical Therapeutics|September 4, 2013
A population approach to the rational use of therapeutic interventionsMichael D Rawlins
Lancet (London, England)|March 4, 2014
Engaging with health-care policyMichael D Rawlins
Expert Review of Clinical Pharmacology|January 24, 2014
Clinical pharmacologists in pharmacoeconomics: what is their role?Michael D Rawlins
The Lancet. Oncology|October 1, 2011
The opportunity cost of cancer care: a statement from NICEMichael D Rawlins, Kalipso Chalkidou
BMJ (Clinical Research Ed.)|July 24, 2004
National Institute for Clinical Excellence and its value judgmentsMichael D Rawlins, Anthony J Culyer
JAMA|November 24, 2005
Quality, innovation, and value for money: NICE and the British National Health ServiceSteven D Pearson, Michael D Rawlins
Clinical Medicine (London, England)|March 12, 2013
What's happening at NICE?Michael D Rawlins, Andrew Dillon, Gillian Leng
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|November 26, 2004
NICE and the public healthMichael D Rawlins
Nature Reviews. Drug Discovery|April 3, 2004
Cutting the cost of drug development?Michael D Rawlins
Journal of the Royal Society of Medicine|January 30, 2013
Of snarks, boojums and national drug chartsMichael D Rawlins
Clinical Therapeutics|September 4, 2013
A population approach to the rational use of therapeutic interventionsMichael D Rawlins
Lancet (London, England)|March 4, 2014
Engaging with health-care policyMichael D Rawlins
Expert Review of Clinical Pharmacology|January 24, 2014
Clinical pharmacologists in pharmacoeconomics: what is their role?Michael D Rawlins
The Lancet. Oncology|October 1, 2011
The opportunity cost of cancer care: a statement from NICEMichael D Rawlins, Kalipso Chalkidou
BMJ (Clinical Research Ed.)|July 24, 2004
National Institute for Clinical Excellence and its value judgmentsMichael D Rawlins, Anthony J Culyer
JAMA|November 24, 2005
Quality, innovation, and value for money: NICE and the British National Health ServiceSteven D Pearson, Michael D Rawlins
Clinical Medicine (London, England)|March 12, 2013
What's happening at NICE?Michael D Rawlins, Andrew Dillon, Gillian Leng
Pageof 4